Yes. I was clearly careless in skimming through most of the article even though one of the lines i quoted also indicated he was only considering cancer drugs. However my point still holds. IMO the marketcap is indicative of how valuable the drug is to the company and a 300 M limit cannot be used to predict whether a trial would be successful. Consider CRIS which was less than 200M before the BCC results. Even EXEL may not have had a 300M MC before the MTC results if the market hadn't known that cabo was active in PC.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.